125 related articles for article (PubMed ID: 38608322)
1. Boosting predictive models and augmenting patient data with relevant genomic and pathway information.
Buosi S; Timilsina M; Torrente M; Provencio M; Fey D; Nováček V
Comput Biol Med; 2024 May; 174():108398. PubMed ID: 38608322
[TBL] [Abstract][Full Text] [Related]
2. Synergy between imputed genetic pathway and clinical information for predicting recurrence in early stage non-small cell lung cancer.
Timilsina M; Fey D; Buosi S; Janik A; Costabello L; Carcereny E; Abreu DR; Cobo M; Castro RL; Bernabé R; Minervini P; Torrente M; Provencio M; Nováček V
J Biomed Inform; 2023 Aug; 144():104424. PubMed ID: 37352900
[TBL] [Abstract][Full Text] [Related]
3. Integration of Clinical Information and Imputed Aneuploidy Scores to Enhance Relapse Prediction in Early Stage Lung Cancer Patients.
Timilsina M; Buosi S; Fey D; Janik A; Torrente M; Provencio M; Bermu Dez AC; Carcereny E; Costabello L; Abreu DRI; Cobo M; Castro RLP; Bernabe R; Guirado DM; Minervini P; Nova Cˇek VI
AMIA Annu Symp Proc; 2022; 2022():1062-1071. PubMed ID: 37128408
[TBL] [Abstract][Full Text] [Related]
4. Machine Learning-Assisted Recurrence Prediction for Patients With Early-Stage Non-Small-Cell Lung Cancer.
Janik A; Torrente M; Costabello L; Calvo V; Walsh B; Camps C; Mohamed SK; Ortega AL; Nováček V; Massutí B; Minervini P; Campelo MRG; Del Barco E; Bosch-Barrera J; Menasalvas E; Timilsina M; Provencio M
JCO Clin Cancer Inform; 2023 Jul; 7():e2200062. PubMed ID: 37428988
[TBL] [Abstract][Full Text] [Related]
5. A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma.
Jones GD; Brandt WS; Shen R; Sanchez-Vega F; Tan KS; Martin A; Zhou J; Berger M; Solit DB; Schultz N; Rizvi H; Liu Y; Adamski A; Chaft JE; Riely GJ; Rocco G; Bott MJ; Molena D; Ladanyi M; Travis WD; Rekhtman N; Park BJ; Adusumilli PS; Lyden D; Imielinski M; Mayo MW; Li BT; Jones DR
JAMA Surg; 2021 Feb; 156(2):e205601. PubMed ID: 33355651
[TBL] [Abstract][Full Text] [Related]
6. A novel 12-gene signature as independent prognostic model in stage IA and IB lung squamous cell carcinoma patients.
Wang K; Li Y; Wang J; Chen R; Li J
Clin Transl Oncol; 2021 Nov; 23(11):2368-2381. PubMed ID: 34028782
[TBL] [Abstract][Full Text] [Related]
7. A comparison of machine learning methods for predicting recurrence and death after curative-intent radiotherapy for non-small cell lung cancer: Development and validation of multivariable clinical prediction models.
Hindocha S; Charlton TG; Linton-Reid K; Hunter B; Chan C; Ahmed M; Robinson EJ; Orton M; Ahmad S; McDonald F; Locke I; Power D; Blackledge M; Lee RW; Aboagye EO
EBioMedicine; 2022 Mar; 77():103911. PubMed ID: 35248997
[TBL] [Abstract][Full Text] [Related]
8. Machine learning application in personalised lung cancer recurrence and survivability prediction.
Yang Y; Xu L; Sun L; Zhang P; Farid SS
Comput Struct Biotechnol J; 2022; 20():1811-1820. PubMed ID: 35521553
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a novel mRNA signature for predicting early relapse in non-small cell lung cancer.
Lin J; Weng J; Lin S; Lin C; Huang J; Zhang C; Zhang S; Dong C; Ji H; Ke X
Jpn J Clin Oncol; 2021 Aug; 51(8):1277-1286. PubMed ID: 34037221
[TBL] [Abstract][Full Text] [Related]
10. Identifying CpG methylation signature as a promising biomarker for recurrence and immunotherapy in non-small-cell lung carcinoma.
Luo R; Song J; Xiao X; Xie Z; Zhao Z; Zhang W; Miao S; Tang Y; Ran L
Aging (Albany NY); 2020 Jul; 12(14):14649-14676. PubMed ID: 32723974
[TBL] [Abstract][Full Text] [Related]
11. Prediction of pathologic stage in non-small cell lung cancer using machine learning algorithm based on CT image feature analysis.
Yu L; Tao G; Zhu L; Wang G; Li Z; Ye J; Chen Q
BMC Cancer; 2019 May; 19(1):464. PubMed ID: 31101024
[TBL] [Abstract][Full Text] [Related]
12. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
13. Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study.
Lococo F; Boldrini L; Diepriye CD; Evangelista J; Nero C; Flamini S; Minucci A; De Paolis E; Vita E; Cesario A; Annunziata S; Calcagni ML; Chiappetta M; Cancellieri A; Larici AR; Cicchetti G; Troost EGC; Ádány R; Farré N; Öztürk E; Van Doorne D; Leoncini F; Urbani A; Trisolini R; Bria E; Giordano A; Rindi G; Sala E; Tortora G; Valentini V; Boccia S; Margaritora S; Scambia G
BMC Cancer; 2023 Jun; 23(1):540. PubMed ID: 37312079
[TBL] [Abstract][Full Text] [Related]
14. Unveiling the potential of proteomic and genetic signatures for precision therapeutics in lung cancer management.
Srivastava S; Jayaswal N; Kumar S; Sharma PK; Behl T; Khalid A; Mohan S; Najmi A; Zoghebi K; Alhazmi HA
Cell Signal; 2024 Jan; 113():110932. PubMed ID: 37866667
[TBL] [Abstract][Full Text] [Related]
15. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of hypoxia-derived gene signatures to predict clinical outcomes and therapeutic responses in stage I lung adenocarcinoma patients.
Shi R; Bao X; Unger K; Sun J; Lu S; Manapov F; Wang X; Belka C; Li M
Theranostics; 2021; 11(10):5061-5076. PubMed ID: 33754044
[No Abstract] [Full Text] [Related]
17. Extensive prediction of drug response in mutation-subtype-specific LUAD with machine learning approach.
Jia K; Wang Y; Cao QI; Wang Y
Oncol Res; 2023; 32(2):409-419. PubMed ID: 38186568
[TBL] [Abstract][Full Text] [Related]
18. Revisiting miRNA Association with Melanoma Recurrence and Metastasis from a Machine Learning Point of View.
Korfiati A; Grafanaki K; Kyriakopoulos GC; Skeparnias I; Georgiou S; Sakellaropoulos G; Stathopoulos C
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163222
[TBL] [Abstract][Full Text] [Related]
19. Integration of Cancer Genomics Data for Tree-based Dimensionality Reduction and Cancer Outcome Prediction.
Shi M; Wang J; Zhang C
Mol Inform; 2020 Mar; 39(3):e1900028. PubMed ID: 31490641
[TBL] [Abstract][Full Text] [Related]
20. A Recurrence-Specific Gene-Based Prognosis Prediction Model for Lung Adenocarcinoma through Machine Learning Algorithm.
Xu S; Zhou J; Liu K; Chen Z; He Z
Biomed Res Int; 2020; 2020():9124792. PubMed ID: 33224985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
